Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.
about
Post-operative radiation therapyDisease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancerHow individual participant data meta-analyses have influenced trial design, conduct, and analysisImproving survival of patients with locally advanced non-small-cell cancer remains a challenge: comment to PROCLAIM.Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis.Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.Have adjuvant tyrosine kinase inhibitors lost their shine?Original Research: Label-free detection for radiation-induced apoptosis in glioblastoma cells.Multistate Statistical Modeling: A Tool to Build a Lung Cancer Microsimulation Model That Includes Parameter Uncertainty and Patient Heterogeneity.Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.Clinical significance of post-progression survival in lung cancerA Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses.Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.Charged-particle therapy in cancer: clinical uses and future perspectives.Surrogate endpoints for overall survival in lung cancer trials: a review.Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials.Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points.Survival analyses in lung cancer.A quantitative method for measurement of HL-60 cell apoptosis based on diffraction imaging flow cytometry technique.Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data.Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis.Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer.Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.Do immune checkpoint inhibitors need new studies methodology?EGFR targeted therapy for lung cancer: are we almost there?
P2860
Q26830376-F604CA0A-EA29-472F-A011-083D54915695Q26860637-057278DE-8B1B-478F-85D1-FF431B47D9D0Q27002509-B86470C6-36DA-44BC-BF29-40CF437CEEE4Q28607751-2E27F22C-946A-44F7-9338-5BE1958C2282Q30382413-26A0305D-91E3-4BE4-B109-31952C3F46AFQ33648808-A683597B-3BAE-496F-B58A-2B753CDC12B4Q35825822-5BE4D657-3B65-452D-B121-575313D7F914Q36162509-83E0B1D7-DDA1-4B8B-A406-DD73E80A229CQ36215439-2002E06B-3CCE-46C7-A960-4527D7B26438Q36288418-231C3649-1CA3-40E3-9162-A43D9BC2654FQ36525431-F5638ADB-5C8C-4C1F-BACD-70B452791495Q37165982-7BCF697B-47EF-417E-8BA6-912D9D55DE4CQ37265409-11E92516-4477-46EE-8C30-165B903BECD6Q37467507-D2E0620E-6215-402B-8333-54C4C60828AFQ37513753-170AFA29-6F8D-4B0E-AA15-51B24DB0E9B2Q38356102-533577BE-6118-45F9-BABC-20A9C1C72B28Q38669447-4B54882B-00A3-48A7-A5B7-66B08617E954Q38691539-FBE5D8FB-8ECB-4495-8922-1454697E0708Q38730533-7E8A9CEB-978F-4192-95C0-04DB23F4DF9AQ38746213-9924550C-4B3A-42F9-8473-273AA9F9880BQ38841987-3E7BAFFA-66D0-4499-9124-053CAE3ED098Q38880510-459F1F85-2AC0-43DB-BBE5-E5802F0FFE7DQ39034554-78C34BA0-608D-4180-802E-57F6B834469DQ39933767-4F17649F-E162-4E67-AFD8-7E0147B4A883Q40824695-DE060A15-FFED-40CC-8545-478B7018E4C8Q41756947-9FDC1D7F-876F-4E1F-926C-AA6859011033Q41848070-D7A76D73-0812-4DBB-86C1-0A7B600213EEQ41865845-052CD2D2-78C3-4BC8-8164-F0666A24F0FBQ42344282-C0FAE3A8-2D2A-459F-86AD-281EF963BE7DQ42738808-216DAB27-10D3-4867-B641-99EA7CA5908AQ47098597-42BFEA3E-8314-420F-8F7D-7AAC4C5D7FAEQ47224555-8552D9CA-E1E8-4778-A5D1-8ED482F20D8BQ47278600-FC053544-9E91-423D-98C6-35746A07780DQ53717818-B9928828-BD5C-486A-AC8C-30B81DA66DD2Q55079845-3A77E47C-939F-414C-BC0C-878AC647CDADQ55304879-812885AE-1D5B-45AB-AFB9-5A746386BCFBQ55375458-02DF617E-2FB6-4FD1-A9F8-271655B065E9Q55405362-BBB575F5-8EA7-4DA1-9169-CD69E72B20EA
P2860
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Surrogate endpoints for overal ...... of individual patients' data.
@ast
Surrogate endpoints for overal ...... of individual patients' data.
@en
type
label
Surrogate endpoints for overal ...... of individual patients' data.
@ast
Surrogate endpoints for overal ...... of individual patients' data.
@en
prefLabel
Surrogate endpoints for overal ...... of individual patients' data.
@ast
Surrogate endpoints for overal ...... of individual patients' data.
@en
P2093
P2860
P50
P921
P1433
P1476
Surrogate endpoints for overal ...... of individual patients' data.
@en
P2093
Caroline Domerg
Cécile Le Pechoux
David Fisher
Frances A Shepherd
Herbert Pang
Jayne F Tierney
Jeffrey Crawford
Laurence Collette
Mahesh Parmar
Mary O'Brien
P2860
P304
P356
10.1016/S1470-2045(13)70158-X
P577
2013-05-14T00:00:00Z